William Blair Has Bearish Estimate for Biodesix Q2 Earnings

Biodesix, Inc. (NASDAQ:BDSX) – Stock analysts at William Blair reduced their Q2 2025 earnings per share estimates for shares of Biodesix in a research note issued on Wednesday, May 14th. William Blair analyst A. Brackmann now forecasts that the company will post earnings of ($0.07) per share for the quarter, down from their previous estimate of ($0.06). William Blair has a “Market Perform” rating on the stock. The consensus estimate for Biodesix’s current full-year earnings is ($0.35) per share. William Blair also issued estimates for Biodesix’s Q3 2025 earnings at ($0.06) EPS, FY2025 earnings at ($0.25) EPS, Q1 2026 earnings at ($0.06) EPS, Q2 2026 earnings at ($0.04) EPS, Q4 2026 earnings at ($0.02) EPS and FY2026 earnings at ($0.15) EPS.

BDSX has been the topic of several other research reports. Lake Street Capital cut their price objective on Biodesix from $3.00 to $2.00 and set a “buy” rating on the stock in a report on Wednesday. Canaccord Genuity Group cut their price objective on Biodesix from $2.50 to $1.50 and set a “buy” rating on the stock in a report on Wednesday. Finally, Craig Hallum dropped their target price on Biodesix from $3.00 to $1.50 and set a “buy” rating on the stock in a report on Wednesday. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $2.00.

Biodesix Price Performance

NASDAQ BDSX opened at $0.30 on Friday. The stock’s 50-day moving average price is $0.57 and its two-hundred day moving average price is $0.99. The company has a current ratio of 3.40, a quick ratio of 3.40 and a debt-to-equity ratio of 1.30. The company has a market cap of $44.11 million, a PE ratio of -0.77 and a beta of 1.18. Biodesix has a 1 year low of $0.17 and a 1 year high of $2.04.

Biodesix (NASDAQ:BDSX) last posted its quarterly earnings data on Tuesday, May 13th. The company reported ($0.08) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.08). The firm had revenue of $17.96 million for the quarter, compared to the consensus estimate of $19.50 million. Biodesix had a negative return on equity of 275.79% and a negative net margin of 66.84%.

Hedge Funds Weigh In On Biodesix

Large investors have recently made changes to their positions in the business. Balyasny Asset Management L.P. acquired a new position in Biodesix in the fourth quarter worth approximately $29,000. Barclays PLC increased its holdings in Biodesix by 1,140.5% in the third quarter. Barclays PLC now owns 23,036 shares of the company’s stock worth $41,000 after buying an additional 21,179 shares during the last quarter. Boothbay Fund Management LLC acquired a new position in Biodesix in the fourth quarter worth approximately $52,000. XTX Topco Ltd acquired a new position in Biodesix in the first quarter worth approximately $64,000. Finally, MYDA Advisors LLC acquired a new position in Biodesix in the fourth quarter worth approximately $76,000. Institutional investors and hedge funds own 20.96% of the company’s stock.

Biodesix Company Profile

Biodesix, Inc operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules.